<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Rohit Malpani on Medium]]></title>
        <description><![CDATA[Stories by Rohit Malpani on Medium]]></description>
        <link>https://medium.com/@romalpani?source=rss-17786a3efd3e------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/0*X6HI2pS6Jm0b8nSt.jpg</url>
            <title>Stories by Rohit Malpani on Medium</title>
            <link>https://medium.com/@romalpani?source=rss-17786a3efd3e------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Sat, 21 Nov 2026 16:51:16 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@romalpani/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Remarks for Health Action International 40th Anniversary]]></title>
            <link>https://romalpani.medium.com/remarks-for-health-action-international-40th-anniversary-birthday-a74637dcfc10?source=rss-17786a3efd3e------2</link>
            <guid isPermaLink="false">https://medium.com/p/a74637dcfc10</guid>
            <category><![CDATA[big-tech]]></category>
            <category><![CDATA[artificial-intelligence]]></category>
            <category><![CDATA[pharmaceutical-industry]]></category>
            <category><![CDATA[civil-society]]></category>
            <dc:creator><![CDATA[Rohit Malpani]]></dc:creator>
            <pubDate>Tue, 25 May 2021 18:58:11 GMT</pubDate>
            <atom:updated>2021-05-25T19:01:09.298Z</atom:updated>
            <content:encoded><![CDATA[<p>These were remarks I delivered as part of a panel to celebrate Health Action International’s 40th Anniversary:</p><p>Congratulations to HAI on its 40th anniversary and for all the work you have done to strengthen the voices of advocates and communities, to ensure independent and public health driven policy making, and to promote needs-based innovation and access to medicines. I am honoured to speak here.</p><p>I wanted to start by talking about myths. As some of you have read in the book Sapiens, societies are based on useful fictions, or myths, which have allowed groups of humans to cooperate in large numbers.</p><p>Myths are also used in many other contexts, whether influencing how countries relate to each other, and for our panel today, for corporations to justify their policies and practices.</p><p>The pharmaceutical industry has successfully used two myths over the last forty years. From 1980 onwards, drug companies sold a myth that most governments were free riding off their efforts, and that only patent monopolies could ensure that countries would pay their fair share for research and development. This myth was tremendously successful in justifying the global expansion of intellectual property rights through the TRIPS Agreement, and the success of drug companies to continue expanding intellectual property rights over the last twenty years.</p><p>The second myth started emerged right around 2000, as drug companies faced widespread criticisms for their practices, and intellectual property rules were coming under criticism for both exorbitant prices of medicines and a lack of research and development for neglected diseases. Drug companies started to sell a myth that voluntary approaches could solve these interrelated crises.</p><p>And even as the first myth never disappeared, the second myth, that somehow drug companies would do the right thing, has taken hold and has put us in the situation we are in today.</p><p>The problem is that as civil society, we have not pushed back against this second myth, and arguably made it easier for it to take hold, thereby allowing drug companies to legitimise voluntary approaches to systemic problems. It has also allowed drug companies to be accepted as legitimate stakeholders in global health.</p><p>One could argue that however imperfect, measures such as the Doha Declaration and the push back against the pharmaceutical industry twenty years ago was indicative of a real momentum towards accountability — red lines that neither governments not companies could cross — and a sense that overcoming AIDS and promoting access to medicines had to be determined collectively by governments and those living with or at high risk of HIV.</p><p>Yet the pharmaceutical industry chipped away at this momentum, and as that sense of ‘never again’ slowly weakened, and as we forgot what led to those initial gains, we, as civil society, have collectively moved towards an approach to access to medicines too grounded in voluntarism — an idea that the drug industry could somehow be co-opted to do the right thing.</p><p>The language of win-win approaches was not just espoused by industry, but by all of us, for example in the voluntary license agreements signed by companies, and in the new partnerships to develop medicines on behalf of neglected patients.</p><p>I understand the reasons for this approach, and the importance of achieving tangible progress when people’s lives are at stake. I was and still am a part of this. But I have to ask myself, did we sacrifice our long-term goals through these near-term efforts? Were we always clear eyed that there was going to be a downside to win-win approaches to access to medicines? Have we become too focused on solutionism to issues and challenges that do not require solutions, but require political tension and to some extent the messy back and forth of competing interests fought out in the public square?</p><p>The win-win approach worked over the last decade because there was no real pain or trade-off for the winners — drug companies and high-income country governments. By that I mean drug companies got their profits and repaired their reputations, wealthy countries could afford to support the response and improve their standing, and low- and middle-income countries got access to low-cost medicines on terms set by drug companies. Yet ‘win-win’ solutions only work when those with power do not have their power or profits challenged, and when the disease itself only affects people living elsewhere. If the more powerful side has to make a sacrifice or may actually lose something — the win-win solution becomes a win-lose ‘free for all’, and as we have seen today, we know the outcome.</p><p>And indeed, we have to ask ourselves, what did a decade of trying to move industry in the right direction get us? Companies — new and old — have ripped up the rule book we thought we were playing by. We thought there was a common set of assumptions and norms in how we approach access to medicines, but there was not.</p><p>I do think of course that a lot of progress has been made in the last year. We have stopped worrying about being seen as reasonable. We are less focused on representation and perhaps more focused on levying criticism for failures. And most importantly we have made tough demands for systematic solutions — such as for decentralised manufacturing or to introduce a TRIPS waiver.</p><p>But of course, it should give us pause that the G20 ended up exactly where it should not have — which is to adopt a voluntary approach to bringing forward new vaccines and other medical technologies in the coming period.</p><p>Taking a step back, perhaps the wider issue is if the boundary between the function of civil society and that of governments and institutions has become too blurred. We have jumped through all the hoops they have put out for us — we make the right technical arguments, we compile the evidence, and we even have designed the ideal system for making pharmaceuticals affordable and available for all. Many of us have sought to work within these institutions and governments in the hope that we can make the system work better.</p><p>But again, perhaps we need to be less reasonable. We need to be comfortable with sticking out like a sore thumb. And we need to be clear where our participation ends and where accountability for governments and companies begin.</p><p>I think it is important to rethink how we work because the challenges ahead will be even more transformative, and more dangerous, as the pandemic recedes from view. In the last few years, big tech companies, and many other tech firms, have slowly emerged as critical participants in our health care systems, for now in the US and Europe, but increasingly in low- and middle-income countries. These companies are not just seeking to work in one part of the healthcare system but all of it — including the development of new drugs and diagnostics, in providing primary care and mental health services, in managing public health surveillance, and in gathering data to improve the predictive capacity of artificial intelligence for a range of purposes, including predicting who will get diseases, when people will get diseases, and who may have already have a disease but does not yet know it.</p><p>These are not companies looking to integrate into our health systems, but to disrupt them, and to eventually fashion them into their own image — much as they have done to our media, our political systems, and how we relate to each other. We have to face a whole new range of concerns — of the loss of individual autonomy, of racial bias in the algorithms deployed by these companies, of not understanding how an algorithm arrives at a decision, and the use of data and machine learning to develop ever more personalised products and services that are not appropriate for most people and most contexts.</p><p>Therefore, as civil society, our challenge will not just be to understand the language of digital health, artificial intelligence and machine learning, but to build new linkages to civil society groups that have already been addressing the impacts of tech companies in other domains, and returning to my original remarks, to consider how we seek to challenge these companies to ensure that their choices and actions are not those that they want but those that are required.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=a74637dcfc10" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Why global governance failed during COVID-19.]]></title>
            <link>https://romalpani.medium.com/why-global-governance-failed-during-covid-19-d855cc29b2d1?source=rss-17786a3efd3e------2</link>
            <guid isPermaLink="false">https://medium.com/p/d855cc29b2d1</guid>
            <category><![CDATA[global-governance]]></category>
            <category><![CDATA[gates-foundation]]></category>
            <category><![CDATA[covid19]]></category>
            <category><![CDATA[access-to-medicines]]></category>
            <dc:creator><![CDATA[Rohit Malpani]]></dc:creator>
            <pubDate>Thu, 29 Apr 2021 14:14:09 GMT</pubDate>
            <atom:updated>2021-04-29T14:14:09.311Z</atom:updated>
            <content:encoded><![CDATA[<p><em>I joined this </em><a href="https://globalhealth.harvard.edu/event/reimagining-pandemic-preparedness-making-equity-a-strategic-priority/"><em>panel discussion</em></a><em> today on the failures of global governance during the COVID-19 pandemic. These were my short remarks at the start of the discussion.</em></p><p>We should acknowledge that more than a year into the pandemic, many of the systems that had been designed for just this moment — surveillance systems, track and trace systems, and even our political systems, have not functioned as they were intended to.</p><p>However, I would argue that the pharmaceutical system we have is working exactly as it is intended to — or how it has been designed.</p><p>This was a broken system when we entered the pandemic, and it is likely to remain a broken system when we exit — but collectively we have long tolerated this system as ‘good enough’. It’s a pharmaceutical system which has always rationed access to low and middle income countries — whether we mean access to scientific resources, financial resources, or end products.</p><p>Two million people die every year of tuberculosis, almost all of them in low and middle income countries, and yet no new vaccine has been developed for a century, and the preferred drug regimens for people with drug resistant TB are expensive, lengthy, and are not highly effective.</p><p>But all of this, at least to the general public, has been mostly invisible.</p><p>The COVID pandemic is making us question the pharmaceutical system, or at least how we behave within it, because the inequity is too obvious to ignore, or perhaps too easy to describe.</p><p>But again, I would argue the system is performing as intended and as it has in the past — in four ways.</p><p>First, public investments of funds — over 100 billion dollars — and publicly funded technology have been privatised with no benefit or rights back to the public sector and public interest.</p><p>Second, all of the products have been claimed by a narrow set of high income countries and wealthy populations, while everyone else has to wait at the back of the line.</p><p>Third, drug companies have earned outsized profits and will continue to do so for the duration of the pandemic — Pfizer expects 30 billion dollars in revenues just this year.</p><p>And fourth, when everything falls apart, as it has, we scramble to put in place inadequate voluntary measures to compensate for our failures — and create what I would call a new ‘charitable equilibrium’.</p><p>The problem with global governance is not that it has created this failure, but people at the controls never seriously believed that we would end up in this place. I would even argue that many of their decisions have made the situation worse.</p><p>Global health agencies have not been transparent. Drug companies are feted as equal partners and even saviours instead of arms-length entities that have a different set of short and long term interests. And too much trust was placed in the main government funders of R&amp;D — who ultimately were more focused on securing their own supplies and needs instead of pushing for worldwide sharing of knowledge and mass production. And in spite of all the rhetoric, these behaviours are accelerating — the European Union has already booked nearly two billion doses of vaccines for the next two years, and the UK has reserved an additional 60 million doses this year to provide its population with a third dose, even as most people will not have had their first.</p><p>This failure in global governance is also built on many bad decisions from the last two decades, and the lessons that were learned and then unlearned after the initial catastrophe of the AIDS pandemic. In the early part of this century, there was a momentum towards accountability — red lines that neither governments nor companies could cross — and a sense that overcoming AIDS in a fair and equitable manner was to be determined by all governments collectively and by those living with or at high risk of HIV. Yet as the sense of ‘never again’ waned away, and as we forgot what produced success, we moved towards an approach to HIV more grounded in voluntarism, of philanthropy and charity, and of the drug industry as partners in the response. This ‘win-win’ approach largely worked because there was no real pain or trade off for the winners — namely pharmaceutical companies and wealthy countries.</p><p>By that I mean drug companies got their profits and repaired their reputations, wealthy countries could afford to support the response and improve their standing, and low and middle income countries got access to low cost medicines on terms set by drug companies. Yet ‘win-win’ solutions only work when those with power do not have their power or profits challenged, and when the disease itself only affects people living elsewhere. If the more powerful side has to make a sacrifice or may actually lose something — the win-win solution becomes a win-lose ‘free for all’, and we all know who ends up having to suffer.</p><p>And finally, if there is one major difference between the early response in 2000 to HIV and the situation we are in today, it is the role of the Gates Foundation. The Gates Foundation designed much of the international response to the pandemic. It championed drug companies as partners and saviours. It refused to acknowledge intellectual property rights as a barrier to access and placed a large bet on capacity reservations and advance purchase commitments — both of which have largely failed — whether one looks at the distribution of diagnostics, monoclonal antibodies, and of course vaccines. Bill Gates now speaks out against the TRIPS waiver — even after 100 governments, Members of Congress, and former Heads of State and Nobel Prize winners, support it. To state the obvious, the whole purpose of the Gates Foundation’s approach, and of course of any philanthropy, is to make the current system work, no matter how badly it is performing.</p><p>It’s a relief the Gates Foundation was not involved in the early AIDS response. What would have happened if, like Bill Gates states today with respect to vaccines, and much as drug companies did in 2000, that companies and public producers in low and middle income countries were not capable of producing AIDS medicines without grants, technical assistance, and permission from the Gates Foundation and the pharmaceutical industry. How much more of a catastrophe would we have had?</p><p>And so we have a choice — either we have an approach to pandemic preparedness and response that is based on the messy, but collective will of governments and societies and based on evidence of what works, or we allow a single individual, leading an unaccountable, opaque and unelected foundation, to make these decisions on behalf of everyone. We cannot have both.</p><p>We also must be honest about whether we can continue to tolerate a system that works for so few and that is broken for so many. If we do continue to tolerate the way things are, at least we know we are doing so with our eyes wide open.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=d855cc29b2d1" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[‘We’re not dealing with bad apples. We’re dealing with a rotten tree.’]]></title>
            <link>https://romalpani.medium.com/were-not-dealing-with-bad-apples-we-re-dealing-with-a-rotten-tree-a9abf0b3cdb6?source=rss-17786a3efd3e------2</link>
            <guid isPermaLink="false">https://medium.com/p/a9abf0b3cdb6</guid>
            <category><![CDATA[covid19]]></category>
            <category><![CDATA[vaccine-nationalism]]></category>
            <category><![CDATA[systems-thinking]]></category>
            <category><![CDATA[access-to-medicines]]></category>
            <dc:creator><![CDATA[Rohit Malpani]]></dc:creator>
            <pubDate>Mon, 26 Apr 2021 08:26:49 GMT</pubDate>
            <atom:updated>2021-04-26T08:38:11.134Z</atom:updated>
            <content:encoded><![CDATA[<p>I am a fan of Trevor Noah and especially over the last year for his observations about race and policing in the United States. A recent <a href="https://www.youtube.com/watch?v=FhhBocZnkoQ">monologue </a>from the Daily Show host about the American system of policing resonated because it is how I often think about our current pharmaceutical system, and its consequences during this pandemic. Starting at 3:33, Noah remarks (which I have edited a bit for brevity):</p><blockquote>The system is more powerful than any individual. The system in policing is doing exactly what it is meant to do in America — and that is to keep poor people in their place — who happens to be the most poor in America — black people….It’s a system. It’s not broken, it’s working the way it’s designed to work. And once you realise that….you realise..oh…we are not dealing with bad apples, we are dealing with a rotten tree — that happens to grow good apples. But for the most part, the tree that was planted, is bearing the fruit that it was intended to.</blockquote><p>This weekend marks <a href="https://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution/">one billion doses</a> of COVID-19 vaccines administered globally. If we assume that there had been ‘absolute fairness’ in vaccine allocation (e.g. vaccines were shipped to each country according to its population size) — every country would have vaccinated a bit more than five percent of its population — enough to vaccinate all healthcare workers, as well as those at the highest risk of severe morbidity or mortality. Of course, things have not worked out that way — wealthy countries account for 16 percent of the world’s population but have acquired more than half of all vaccine doses. As of <a href="https://news.un.org/en/story/2021/04/1089392">mid-April</a>, rich countries have administered 87 percent of all doses, while low-income countries have administered just 0.2 percent of all COVID-19 vaccines.</p><p>Things have worked out exactly as the current pharmaceutical system was engineered — it is — to quote Trevor Noah — ‘working the way it’s designed to work’.</p><p>For those countries on the wrong side of the vaccine divide today, there is a grim familiarity — this is not a new story but one that gets retold with a different cast of characters (and products). Previous versions of this story may not have been about such naked competition for supply — that is unique to the COVID-19 pandemic — but the story of our pharmaceutical system is one that is designed to promote and exacerbate exclusion, injustice, and immoral behaviour, which ultimately results in — to use polite, sterile public health terminology — ‘avoidable morbidity and mortality’.</p><p>Over the last few decades, we (access advocates) have spent our careers calling for measures to overcome one ‘market failure’ before moving on to the next one. It is because of those experiences, and the bitter lessons of each access fight, that advocates warned last year that without drastic measures, there would eventually be gross inequity in access to vaccines (and medicines and tests).</p><p>At the somewhat hopeful <a href="https://www.theguardian.com/world/2020/apr/24/us-stays-away-as-world-leaders-agree-action-on-covid-19-vaccine">launch</a> of the ACT Accelerator in April 2020 (the ACT Accelerator is an entity that convenes several global health agencies and foundations to ‘accelerate’ innovation and access to medical technologies), you wanted to believe the words of global leaders who backed and financed the Accelerator while also delivering soaring rhetoric of ‘equitable access for all’. But if you had been involved in pharmaceutical issues for any period of time, you could also imagine these same politicians delivering their message of solidarity and goodwill, and immediately afterwards placing an advance order for vaccines and drugs in development. In the end, not only did the plans to ensure equitable access ignore the lessons of past failures (and successes) of the pharmaceutical system — it allowed the very same high-income country governments and drug companies that have been responsible for the repeated failures of the last thirty years to be in control of the COVID response.</p><p>So what is our pharmaceutical system designed to do?</p><p><strong>First, the pharmaceutical system is designed to convert public resources into private benefit, with nothing going back to the public except a product.</strong> Governments have been responsible for developing, funding, and testing many of the critical technologies that underpin the COVID-19 vaccines, and have also spent well north of <a href="https://www.businesswire.com/news/home/20210110005098/en">90 billion Euros</a> on paying for the development and manufacture of medicines, vaccines, and tests over the last year. Yet these same governments have not secured any ‘public benefit’ in negotiations with drug companies. No transparency — of pricing, of R&amp;D costs, of cost of manufacturing. No sharing of intellectual property or know-how. High prices for the vaccines despite the massive public subsidy. And no workable mechanism to allow governments to take back control if things are not going well (for example, right now).</p><p><strong>Second, the pharmaceutical system is designed to work effectively for the wealthiest and most powerful countries and people, and sub-optimally or not at all for the rest of the world.</strong> For COVID-19, this is in part because high-income countries, who put up most of the funding for technology development, chose to corner supply instead of making demands that would promote the public good (see above). Again, the fact that high-income countries could simply ensure that the system benefits themselves is exactly how the system is designed to work. What is unique about COVID-19 is that since every country needs access to the same technology at the same time, the benefit that the wealthiest countries pursued was first in line access to vaccines, drugs, and tests.</p><p>Historically, as during COVID-19, high-income countries pay for most of the research and development (and comprise a substantial percentage of the pharmaceutical market because they overpay for medicines and vaccines). Since high-income countries both subsidize R&amp;D and overpay for drugs that are approved, companies are encouraged to only focus their resources on developing medicines and vaccines that are of the highest priority to the wealthiest countries while ignoring the unmet needs of low- and middle-income countries (this is also due in part to the priority setting of high-income countries that finance or fund early stage research and drug discovery, although public sector investment into so-called neglected diseases has improved over the last two decades).</p><p>The upshot is that for those diseases that affect neglected populations, there is inadequate investment (in the parlance of the drug industry, investment in these priorities is an ‘opportunity cost’), and thus for people who suffer from such diseases, they must wait at the back of the line for investments in R&amp;D to meet their needs. In other words, the pharmaceutical system has always rationed ‘access’ to the poorest — be it a lack of new medicines or vaccines to prevent or treat neglected diseases, or in the case of COVID-19, little or no supply of COVID-19 vaccines.</p><p>When there has been a groundswell of support to reform the pharmaceutical system in high-income countries, it is mostly focused on ensuring that the prices high-income countries pay are reasonable, instead of reforms that promote equity for all populations, and especially those needs that are ignored or marginalised in the current pharmaceutical system. For example, the major drug industry reform legislation tabled in the U.S. Congress this year is focused almost exclusively on lowering drug prices on behalf of Americans. Similar discussions are underway in Europe.</p><p><strong>Third, the pharmaceutical system is designed to deliver outsized profits to pharmaceutical companies.</strong> That’s obvious, but again, the point here is to say that the system is working exactly as it was designed. Drug companies that have managed to obtain emergency approval for their vaccines are enjoying bumper profits. Pfizer is projecting between <a href="https://www.theguardian.com/business/2021/mar/06/from-pfizer-to-moderna-whos-making-billions-from-covid-vaccines">15 and 30 billion dollars</a> in revenue from its COVID franchise this year, and significant profits in the coming years if it is able to increase the price of its COVID vaccine boosters (that will be required for successive variants). Moderna is likely to emerge from the pandemic as one of the world’s largest drug companies, much as Gilead Sciences vaulted into the ‘big leagues’ from the AIDS pandemic.</p><p><strong>Fourth, once the pharmaceutical system breaks down, there is a scramble to put in place charitable and voluntary measures to mitigate the worst consequences. </strong>With the pandemic out of control in India and Brazil, and perhaps eventually in other countries that have managed to control the pandemic until now, we will now see a hurried raft of voluntary, humanitarian, and philanthropic measures to put a band-aid on an emerging catastrophe. These voluntary initiatives are of course too late to forestall the heavy loss of human life.</p><p>This story is not new. The AIDS pandemic was supposed to have been a ‘never again’ moment — resulting in a transformation of the pharmaceutical industry — as demands for appropriate R&amp;D, affordable prices, and limits on intellectual property had put the industry on the defensive two decades ago. Yet for all the claims that the AIDS pandemic led to a seismic change in the pharmaceutical industry (and global trade rules), the last decade has been noticeably calmer and tamer.</p><p>We have settled instead, with the launch of each new antiretroviral medicine (or medicine to treat a co-infection, such as Hepatitis C), into a predictable dance of charitable measures — such as voluntary licensing and not for profit paediatric research programs — that can ensure that many people living with HIV have adequate and timely access to affordable and effective antiretroviral therapy. Many would argue this has been tremendously beneficial to people with HIV and AIDS and has codified certain expectations of how pharmaceutical companies address the AIDS pandemic. I agree. But because the AIDS pandemic did not force a fundamental rethink of the current pharmaceutical system, we were always setting ourselves up for the next global catastrophe when the ‘polite rules’ that have been established are thrown out the window.</p><p>And so now, with a catastrophe upon us, we are inventing a new ‘charitable equilibrium’ — whether it is the COVAX initiative’s intention of only vaccinating 20 percent of all low-income countries in 2021, or the <a href="https://www.gavi.org/news/media-room/france-makes-important-vaccine-dose-donation-covax">donations</a> by a few high-income countries, such as France, to reach the most at risk and vulnerable populations this year. More hopeful and transformative measures, such as decentralised production of mRNA vaccines or a WTO waiver of IP for COVID-19 technologies, may still succeed, but even if they do, the restrictions on its wider applicability are likely to be significant, and the rest of the pharmaceutical system will lurch along until the next global catastrophe.</p><p>We were never going to have a fair and just global immunisation campaign to address the pandemic. We entered into the pandemic with a broken pharmaceutical system that: allows corporations to take control of public assets and resources with no accountability, provides most of the benefits of the pharmaceutical system (R&amp;D outputs or supply) to a narrow set of high-income countries, assures drug industry profitability during the worst of times, and that falls back on voluntary measures and charity once the death and suffering is too difficult to avoid.</p><p>For those of us who are access advocates — call us ‘storm chasers’ or ‘disaster junkies’ — we move from one access tragedy to the next — knowing how it will unfold and how it will be resolved — even as the same underlying flaws in the pharmaceutical system remain. Real change is not possible unless there is collective anger, and collective demand for reform.</p><p>For people who are on the wrong side of the vaccine divide, there is anger. Right now it may be anger driven by dissonance — of the left-behind looking at images of twenty year olds getting vaccinated in the United States, of Facebook posts of champagne brunches, even as they worry about a sister who is a nurse, a friend who is an asthmatic, or a parent who is pushing 80. I can only hope this anger deepens and expands, and is not just focused on the disaster that is unfolding, but why it is happening, and what can be done to uproot the rotten tree and replace it with something better.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=a9abf0b3cdb6" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Why is the Access to Medicines movement underfunded?]]></title>
            <link>https://romalpani.medium.com/why-is-the-access-to-medicines-movement-underfunded-3442f84fb694?source=rss-17786a3efd3e------2</link>
            <guid isPermaLink="false">https://medium.com/p/3442f84fb694</guid>
            <category><![CDATA[access-to-medicines]]></category>
            <category><![CDATA[global-health]]></category>
            <category><![CDATA[philanthropy]]></category>
            <category><![CDATA[civil-society]]></category>
            <dc:creator><![CDATA[Rohit Malpani]]></dc:creator>
            <pubDate>Tue, 09 Mar 2021 19:24:31 GMT</pubDate>
            <atom:updated>2021-03-09T20:08:20.913Z</atom:updated>
            <content:encoded><![CDATA[<p>Although I have no way of scientifically confirming, I get the sense from recent conversations that many civil society organisations working on ‘access to medicines’ are running low on funding or funding opportunities.</p><p>How strange. We are at a ‘seminal’ moment in access to medicines — the COVID-19 pandemic has brought access to the front pages of every newspaper and news program — and access has become very mainstream (any mention of this topic pre-pandemic would instantly put people to sleep or lead them to run away).</p><p>My diagnosis of the funding landscape could be too pessimistic. But if it’s right, it is worth thinking about why there is scarcity at a time that foundations and philanthropies should be investing heavily in the movement.</p><p>Here are several reasons I would put forward:</p><p>1. <strong>We have the wrong foundations ‘investing’ in access to medicines.</strong> Whereas in previous years there was generous support from the likes of the Ford Foundation and Rockefeller Foundation (alongside the historic and on-going support of the Open Society Foundation), today the space is mostly dominated by the Gates Foundation and the Wellcome Trust — both of whom have made this issue a priority. This should be a boon — these are two of the world’s largest and well-resourced philanthropies.</p><p>Unfortunately, neither of them is really a good fit. Both are more focused on investing in global health agencies, forming partnerships with governments, or investing in companies or research and clinical development. Or, as the New York Times <a href="https://www.nytimes.com/2020/11/23/world/bill-gates-vaccine-coronavirus.html">noted</a> about Bill Gates and his foundation, to essentially manage (or control) international health.</p><p>Both are also very conservative — you could never imagine either foundation supporting any of the activism that underpins the access to medicines movement. The Gates Foundation does support advocacy, but of the milquetoast type — organisations like ONE, the Centre for Global Development, and the Pandemic Action Network — more focused on cheerleading and win-win solutions than the hard-nosed advocacy that has underpinned most of the progress of the last few decades.</p><p>And while it probably merits a separate blog, one could argue that the policies and investments of these two foundations are actively undermining the efforts of organisations who work on access to medicines, something I <a href="https://healthpolicy-watch.news/gates-foundation-address-systemic-covid-19/">wrote</a> about with two colleagues as it relates to the Gates Foundation. The Wellcome Trust is not much better, it has an <a href="https://wellcome.org/what-we-do/our-work/access-healthcare-interventions">underwhelming access policy</a> and actual or potential <a href="https://www.bmj.com/content/372/bmj.n556">conflicts of interest</a> tied to its own investments.</p><p>2. <strong>Efforts to promote innovation and access to medicines are dominated by ideas that are too technical, too friendly, and therefore too simplistic.</strong> The more that access to medicines is equated with ‘complex’ market shaping, innovation partnerships, advanced market commitments, voluntary licensing (though some would disagree on this point), pricing structures, and incentive mechanisms — the more simplistic, counterproductive, and misdirected ‘access to medicines’ becomes. Innovation and access to medicines has always been about power and politics — who has it, who seeks it, and how it is wielded for good (or bad) outcomes. It is messy, chaotic, at times confrontational, and has nothing to do with the endless PowerPoint decks, White Papers, and yes, <a href="https://www.vox.com/science-and-health/2019/12/13/21004456/bill-gates-mckinsey-global-public-health-bcg">management consultants</a>, littering the access landscape.</p><p>One just needs to look at pharmaceutical companies. They may participate in all the pleasantries of partnerships and intellectual convenings, but they continue to <a href="https://www.opensecrets.org/news/2020/12/pharma-lobby-poured-millions-into-darkmoney-groups/">pour millions of dollars</a> into lobbying and influencing and are not afraid to <a href="https://phrma.org/-/media/Project/PhRMA/PhRMA-Org/PhRMA-Org/PDF/P-R/PhRMA_2021-Special-301_Review_Comment-1.pdf">bare their fangs</a> at the first sign of any government stepping out of line. Nevertheless, everyone in global health pretends like this is perfectly fine, and instead look to <a href="https://www.ifpma.org/resource-centre/pharma-industry-body-joins-as-founding-partner-a-new-global-collaboration-to-accelerate-the-development-production-and-equitable-access-to-new-covid-19-tools/">form partnerships</a> with drug corporations instead of challenging them, while shutting out civil society or just kind of ignoring their efforts.</p><p>The point is, the conventional wisdom has shifted so much to these technical interventions that activism now looks unfashionable and irrelevant, consigning those engaged in the political fights to a dark corner of the access universe. This makes it less compelling to foundations and philanthropies which support activism and rights-based approaches. Perhaps they wrongly believe that technical interventions are enough (and therefore the technical investments of Gates and Wellcome are enough), and decide their time and energy is better spent elsewhere.</p><p>3. <strong>The access to medicines ‘community’ has not evolved with the times.</strong> The problem for the access to medicines movement is it tends to be a bit too much of a one-trick pony, focusing on strategies to bring down medicine prices and foster generic competition, or I guess a two-trick pony if you include efforts to encourage development of medicines on behalf of neglected populations and/or ensuring affordability.</p><p>The movement’s focus makes sense of course — this is what matters most and what is the core of the industry’s business. Yet organisations working on access to medicines perhaps could have broadened how they work on access — one criticism is that it was too focused on drugs and did not make space for access issues related to diagnostics and vaccines. Diagnostics and vaccines have become central to the COVID-19 response much more than drugs.</p><p>Another problem is the disease focus was too narrow — the access movement has not really made the case for heavier investment in other areas of need such as non-communicable diseases, antimicrobial resistance, or rare diseases (or have not broadened their efforts sufficiently to these areas of need). A third problem is that even as the technologies have evolved, our strategies and interventions have not. I still do not think most organisations have credible approaches to deal with access challenges for biologics, much less the onrush of new technologies — e.g., mRNA.</p><p>More generally, over the last two decades — pandemic notwithstanding — global health has moved from the centre of development to the periphery — and other critical issues — whether climate change, racial justice, economic inequality, financialization, digital rights etc. have moved to the fore. That is a good thing of course, it was never sustainable to have such a singular focus on health. Yet this should have been a signal for the access to medicines community to reframe its efforts more broadly — whether to look at the <a href="https://globalnews.ca/news/5330863/climate-change-pharmaceutical-companies/">carbon footprint</a> and environmental damage of the industry (or to examine how countries will need to <a href="https://academic.oup.com/trstmh/article/115/2/147/6121885">adapt</a> to climate change through new investments in R&amp;D for neglected tropical diseases), the intersection of racial justice with access to medicines — which I applaud my colleague Priti Krishtel — for <a href="https://www.nytimes.com/2021/02/09/opinion/biden-patent-office.html">tackling</a>, or the growing (and very disturbing) <a href="https://www.ft.com/content/4743d76c-af9b-11e9-8030-530adfa879c2">intersection</a> of the tech and pharmaceutical sectors and the expanding use of artificial intelligence and Big Data by drug companies.</p><p>Then again, the drug industry remains singularly focused on issues of intellectual property and pricing — it is where the rubber hits the road (and how they make their money) — and for the access movement to move into other frames — while perhaps necessary to sustain itself — may leave the drug industry, basking in the false glory of its pandemic response — even more powerful and more capable of securing new monopolies and ever-higher drug prices.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=3442f84fb694" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Vaccine export barriers during a pandemic are wrong.]]></title>
            <link>https://romalpani.medium.com/vaccine-export-barriers-during-a-pandemic-are-wrong-fcde78811725?source=rss-17786a3efd3e------2</link>
            <guid isPermaLink="false">https://medium.com/p/fcde78811725</guid>
            <category><![CDATA[intellectual-property]]></category>
            <category><![CDATA[vaccine-nationalism]]></category>
            <category><![CDATA[covid19]]></category>
            <dc:creator><![CDATA[Rohit Malpani]]></dc:creator>
            <pubDate>Tue, 16 Feb 2021 06:12:37 GMT</pubDate>
            <atom:updated>2021-02-16T06:12:37.491Z</atom:updated>
            <content:encoded><![CDATA[<h3><strong>Vaccine export barriers during a pandemic are wrong. So are intellectual property barriers and vaccine nationalism.</strong></h3><p>In the last few weeks, a global trade war has erupted over equitable access to COVID-19 vaccines. Yet it is the wrong one. High-income countries are fighting over who gets to be first in line for access to COVID-19 vaccines, even after having hoarded most of the world’s supply. In doing so, they are letting pharmaceutical corporations off the hook, and leaving the poorest countries out in the cold.</p><p>The European Union’s decision to <a href="https://ec.europa.eu/commission/presscorner/detail/en/IP_21_307">pull up the drawbridge</a> and potentially restrict exports of COVID-19 vaccines has been met with equal parts consternation and indignation by other wealthy countries. <a href="https://www.ft.com/content/5c15d7ea-aaf6-46f4-924e-30f168dd14dd">Protesting countries</a>, such as Canada and Japan, have benefited handsomely from the current ‘free for all’ that is a defining feature of the pandemic — Canada ‘leads the world’ — having <a href="https://www.theguardian.com/world/2021/jan/29/canada-and-uk-among-countries-with-most-vaccine-doses-ordered-per-person">secured </a>ten doses for every Canadian, with Japan having ‘only’ <a href="https://www.europeanpharmaceuticalreview.com/news/140133/japan-has-pre-ordered-covid-19-vaccine-doses-for-more-than-four-times-its-population-says-report/">secured </a>4 doses per person. If politics, as they say, stops at the water’s edge, so does concern for a fair and equitable trading system.</p><p>In October 2020, faced with a likely reality that their own countries and their neighbours would be left with little to no access to COVID-19 vaccines, the governments of India and South Africa, now supported by nearly all low- and middle-income countries, <a href="https://docs.wto.org/dol2fe/Pages/SS/directdoc.aspx?filename=q:/IP/C/W669.pdf&amp;Open=True">petitioned </a>the World Trade Organization to temporarily suspend all intellectual property rules for COVID-19 medical technologies for the duration of the pandemic. Their concerns about insufficient supplies have been borne out — only <a href="https://www.vox.com/2021/1/29/22253908/rich-countries-hoarding-covid-19-vaccines">55 doses</a> of COVID-19 vaccines have been administered in low-income countries out of a total of more than 138 million doses administered worldwide.</p><p>This situation is not likely to improve. <a href="https://launchandscalefaster.org/COVID-19">Rich countries</a> with 14% of the global population had secured 4.2 billion vaccine doses, versus only 2.4 billion by low- and middle-income countries. These countries are also at the front of the line with options for over 4 billion additional doses still being negotiated. The <a href="https://www.gavi.org/vaccineswork/covax-supply-forecast-reveals-where-when-covid-19-vaccines-will-be-delivered">COVAX facility</a>, which is supposed to facilitate equitable vaccine access, has secured 1.1 billion doses with plans for an additional 1.2 billion, but some of those doses are reserved for upper-income countries, and most will arrive later this year, when many rich countries will have already reached herd immunity.</p><p>Intellectual property rights undermine supply, affordability, and equitable distribution to new COVID-19 vaccines by leaving total control of the knowledge and technology required for each vaccine in the hands of a small group of drug corporations that exclude other producers. We already know that no one company can supply all the vaccines needed to tackle the coronavirus and emerging variants, and we also know that given the choice, companies with limited supply will always sell to the highest bidder, whether that is wealthy countries, big companies, or individuals who want to cut the queue.</p><p>The proposed WTO IP waiver would remove an unnecessary barrier to the sharing of knowledge that is required to scale-up production of vaccines. It would allow any manufacturer willing to invest to make the vaccines for underserved markets. It is not as if intellectual property has played a major role in getting vaccines to market. Prior to the pandemic, coronavirus vaccine research programs were limited to a few academic consortiums, and in the midst of the pandemic, governments have <a href="https://www.businesswire.com/news/home/20210110005098/en">spent over 90 billion Euros</a> to pay for research and development, manufacturing and advanced purchases of new vaccines.</p><p>Yet even though intellectual property rights did not contribute to the rapid development of new COVID vaccines, IP rights are critical for those pharmaceutical corporations that now have exclusive rights and want to maximize profits this year and beyond. Pfizer is projecting <a href="https://www.bloomberg.com/news/articles/2021-02-02/pfizer-forecasts-15-billion-in-covid-vaccine-sales-for-2021">US$ 15 billion</a> in revenues in 2021, and expects to have a <a href="https://www.wsj.com/articles/pfizer-lifts-outlook-on-covid-19-vaccine-posts-weaker-profit-11612270628">‘durable’ </a>revenue stream in the long-term due to the need for boosters against variants. In other words, our collective failure to control the pandemic and have enough supply is directly tied to the industry’s intent to retain its crown-jewel monopolies.</p><p>The European Union was right to criticize AstraZeneca, which signed an <a href="https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-and-oxford-university-announce-landmark-agreement-for-covid-19-vaccine.html">exclusive agreement</a> with Oxford to manufacture a vaccine it had no hand in inventing, for not honoring its commitments. Yet instead of training its power upon rectifying the exclusive control of vaccines with a few multinational companies, they have decided to divide governments against one another, not to mention continuing to ignore the needs of the most vulnerable countries. Even now, the European Union has been <a href="https://www.keionline.org/34275">antagonistic </a>to India’s and South Africa’s request at the WTO, apparently willing to grant drug companies unfettered power to control these vaccines, if they can obtain enough doses for their own population.</p><p>It is not as if other high-income countries are any more virtuous. The same governments that are speaking out against EU export restrictions for depriving them of vaccines for their domestic populations have also been unwilling to support suspending IP rights on COVID-19 medical technologies. Some have been outright <a href="https://www.france24.com/en/live-news/20201210-wto-wrangle-on-covid-vaccines-ip-idea">antagonistic </a>— such as the case with Japan and the United Kingdom, while others such as <a href="https://www.international.gc.ca/world-monde/international_relations-relations_internationales/wto-omc/2020-12-10-TRIPS-ADPIC.aspx?lang=eng">Canada </a>have been unable to commit to supporting the waiver. Of course, this stance reeks of a double standard.</p><p>Export restrictions had an immediate bite on the supplies provided to rich countries, and so they responded quickly. Yet these countries are happy to run out the clock on addressing intellectual property rights since they may believe their immunization programs can ‘outrun’ variants while avoiding supply disruptions in the future. These countries still have the chance to make the right choice, including at a meeting at the WTO in early March. Allowing the free movement of vaccines may allow the wealthiest countries to temporarily exit the pandemic this year, but only by allowing the free movement of knowledge will these countries rectify the inequity of access for which they are responsible, while also encouraging all countries to work with one another to end this pandemic.</p><p><em>Rohit Malpani is a public health consultant and advocate and represents non-governmental organizations on the Board of Unitaid.</em></p><p><em>Brook Baker is a professor at Northeastern University School of Law, USA; an honorary research fellow at the University of KwaZulu Natal; and a senior policy analyst with Health GAP (Global Access Project).</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=fcde78811725" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>